Pure Red Cell Aplasia with CellCept and Myfortic

Healthcare professionals have been notified by the manufacturers of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid) that these drugs, in combination with other immunosuppressive agents, have been associated with cases of pure red cell aplasia. Both drugs are used to prevent organ rejection in transplant patients.

CellCept is made by Roche and Myfortic is made by Novartis. The labeling for these drugs has been changed to reflect the new information.

Pure red cell aplasia is a type of anemia characterized by selective reduction of red blood cell precursors. Patients may present with fatigue, lethargy and pallor. In some cases, reducing the dose or stopping the drug reversed the aplasia, but reducing immunosuppression in transplant patients could place the graft at risk.

Rating:
Tags:
Views: 12

Share Facebook